IGC Pharma vs Longeveron
IGC and LGVN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How IGC and LGVN compare
Longeveron is the larger company, worth 4.4 times as much as IGC Pharma ($79.4M against $18.2M).
IGC Pharma grew revenue faster over the last twelve months (−15.4% versus −18.9% for Longeveron).
IGC Pharma keeps more of each dollar of sales as profit, with a net margin of −702% compared with −1922% at Longeveron.
Longeveron scores higher on the StockData Score (5 against 2 for IGC Pharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | IGC | LGVN |
|---|---|---|
| Size and price | ||
| Market cap | $18.2M | $79.4M |
| Share price | $0.176 | $2.49 |
| Change, 1 year | −51.9% | −64.8% |
| Change, 5 years | −87.7% | −99.8% |
| Beta (5Y) | 0.59 | 1.24 |
| Employees | 67 | 37 |
| StockData Score | ||
| Total score | 2 | 5 (better) |
| Valuation score | 0 | 0 |
| Growth score | 0 | 0 |
| Performance score | 1 (better) | 0 |
| Health score | 1 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 16.2× (better) | 68.1× |
| P/B | 2.8× (better) | 16.9× |
| FCF yield | – | −22.9% |
| Fair value | $0.161 | – |
| Margin of safety | −9.1% | – |
| Growth | ||
| Revenue growth (TTM) | −15.4% (better) | −18.9% |
| Revenue growth, 5Y average | – | −26.6% |
| Profitability | ||
| Gross margin | 21.9% | 66.4% (better) |
| Operating margin | −987% (better) | −2021% |
| Net margin | −702% (better) | −1922% |
| FCF margin | – | −1560% |
| Return on equity | −113% (better) | −305% |
| Return on invested capital | −136% | – |
| Financial health | ||
| Debt / equity | 0.02 (better) | 0.00 |
| Current ratio | 0.42 | 1.25 (better) |
| Altman Z-score | −19.52 | −17.08 (better) |
| Piotroski F-score | – | 1 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 5.1% | 1.5% |
| Held by insiders | 13.2% | 43.8% |
| Short interest, % of float | 0.44% | 0.88% |
Go deeper
- IGC stock overview
- IGC income statement
- IGC valuation and score
- LGVN stock overview
- LGVN income statement
- LGVN valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.